-

Labcorp Named to Fortune® Magazine’s 2022 ‘World’s Most Admired Companies’ List for the Fourth Time

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, has been named to FORTUNE® magazine's 2022 list of the World’s Most Admired Companies, marking its fourth appearance on the list. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, asks top executives, directors and financial analysts to identify the companies with the strongest reputations across various industries.

“Labcorp’s global network of more than 70,000 employees capitalizes on the strength of our comprehensive capabilities to accelerate progress in areas like oncology, women’s health and Alzheimer’s, and to continue supporting the world’s COVID-19 pandemic response efforts,” said Adam Schechter, chairman and CEO of Labcorp. “This recognition underscores the work we do each day to improve health care decisions and outcomes through science, technology and a continued commitment to innovation.”

In 2021, Labcorp played a critical role in the fight against COVID-19 by providing testing options, variant sequencing and assistance in the development of important vaccines and therapies. Additionally, Labcorp’s leading portfolio of offerings supported key advancements in diagnostics and therapies for many different diseases, and the company expanded access to clinical trial opportunities.

FORTUNE's World's Most Admired Companies list is the definitive report card on corporate reputations. Korn Ferry has collaborated with FORTUNE annually since 1997 to identify, select and rank the world’s most admired companies and uncover the business practices that make these companies highly regarded among their peers. To compile the rankings, corporate reputation and performance are measured against nine key attributes: innovation, people management, use of corporate assets, social responsibility, quality of management, financial soundness, long-term investment, quality of products and services and global competitiveness.

The World’s Most Admired Companies list can be found on the FORTUNE website.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn about Labcorp at www.Labcorp.com, or follow us on LinkedIn and Twitter @Labcorp.

Contacts

Media: Michele Mazur – 336-436-8263
media@Labcorp.com

Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com

LABORATORY CORPORATION OF AMERICA HOLDINGS

NYSE:LH
Details
Headquarters: Burlington, NC
CEO: Adam Schechter
Employees: 75,000
Organization: PUB
Revenues: $16.1 billion (2021)
Net Income: $2.37 billion (2021)

Release Versions

Contacts

Media: Michele Mazur – 336-436-8263
media@Labcorp.com

Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com

More News From LABORATORY CORPORATION OF AMERICA HOLDINGS

Ovia HealthTM Expands Digital Platform Capabilities to Include Menopause Tracking

BOSTON--(BUSINESS WIRE)--Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans. According to the National Institute on Aging (NIA), more than 1 million women trans...

Labcorp Announces 2022 Fourth Quarter and Full-Year Results

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance. “We finished the year strong, with accelerated revenue growth in Diagnostics, continued strong underlying fundamentals in Drug Development and margin expansion,” said Adam Schechter, chairman and CEO of Labcorp. “In 2022, we also advanced our strategy with the announcement of the spin of our Clinical...

Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial ma...
Back to Newsroom